Processa Pharmaceuticals (PCSA) Other Non-Current Assets (2012 - 2026)
Processa Pharmaceuticals' (PCSA) quarterly Other Non-Current Assets came in at $993701.0 in Q1 2026, little changed YoY from $993701.0 in Q1 2025, and little changed on a QoQ basis from $993701.0 in Q4 2025.
Processa Pharmaceuticals (PCSA) Other Non-Current Assets (2012 - 2026) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 15 years of Other Non-Current Assets data on file, last reported at $993701.0 in Q1 2026.
- Quarterly Other Non-Current Assets changed 0.0% year-over-year to $993701.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $993701.0 (changed 0.0% YoY) and the FY2025 annual result came in at $993701.0, down 22.03% from the prior year.
- Other Non-Current Assets held at $993701.0 in Q1 2026, from $993701.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $7.7 million in Q3 2022 to a low of $5535.0 in Q1 2022.
- A 5-year average of $789606.1 and a median of $5535.0 in 2022 frame the typical range for Other Non-Current Assets.
- The widest YoY moves for Other Non-Current Assets: up 139335.95% in 2022, down 99.94% in 2022.
- Tracing PCSA's Other Non-Current Assets over 5 years: stood at $5535.0 in 2022, then changed by 0.0% to $5535.0 in 2023, then soared by 22925.15% to $1.3 million in 2024, then retreated by 22.03% to $993701.0 in 2025, then changed by 0.0% to $993701.0 in 2026.
- The last three Other Non-Current Assets figures came in at $993701.0 (Q1 2026), $993701.0 (Q4 2025), and $993701.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 65.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 104.44 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 62.96 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 202.31 Mn |
| 10 | Processa Pharmaceuticals | 5.93 Mn | 5.93 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 993,701.00 |
| Dec 31, 2025 | 993,701.00 |
| Sep 30, 2025 | 993,701.00 |
| Jun 30, 2025 | 5,535.00 |
| Mar 31, 2025 | 993,701.00 |
| Dec 31, 2024 | 1.27 Mn |
| Sep 30, 2024 | 5,535.00 |
| Jun 30, 2024 | 5,535.00 |
| Mar 31, 2024 | 5,535.00 |
| Dec 31, 2023 | 5,535.00 |
| Sep 30, 2023 | 5,535.00 |
| Jun 30, 2023 | 193,140.00 |
| Mar 31, 2023 | 213,322.00 |
| Dec 31, 2022 | 5,535.00 |
| Sep 30, 2022 | 7.72 Mn |
| Jun 30, 2022 | 5,535.00 |
| Mar 31, 2022 | 5,535.00 |
| Dec 31, 2021 | 5,535.00 |
| Sep 30, 2021 | 5,535.00 |
| Jun 30, 2021 | 8.57 Mn |